NEO
Price
$7.31
Change
+$0.14 (+1.95%)
Updated
Jun 30, 04:59 PM (EDT)
Capitalization
2.01B
30 days until earnings call
TMDX
Price
$134.01
Change
+$2.56 (+1.95%)
Updated
Jun 30, 04:59 PM (EDT)
Capitalization
2.4B
31 days until earnings call
Interact to see
Advertisement

NEO vs TMDX

Header iconNEO vs TMDX Comparison
Open Charts NEO vs TMDXBanner chart's image
NeoGenomics
Price$7.31
Change+$0.14 (+1.95%)
Volume$29.65K
Capitalization2.01B
TransMedics Group
Price$134.01
Change+$2.56 (+1.95%)
Volume$5.25K
Capitalization2.4B
NEO vs TMDX Comparison Chart in %
Loading...
NEO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TMDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NEO vs. TMDX commentary
Jul 01, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NEO is a Buy and TMDX is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 01, 2025
Stock price -- (NEO: $7.18 vs. TMDX: $131.45)
Brand notoriety: NEO and TMDX are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: NEO: 93% vs. TMDX: 61%
Market capitalization -- NEO: $2.01B vs. TMDX: $2.4B
NEO [@Medical Specialties] is valued at $2.01B. TMDX’s [@Medical Specialties] market capitalization is $2.4B. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.56B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NEO’s FA Score shows that 0 FA rating(s) are green whileTMDX’s FA Score has 0 green FA rating(s).

  • NEO’s FA Score: 0 green, 5 red.
  • TMDX’s FA Score: 0 green, 5 red.
According to our system of comparison, TMDX is a better buy in the long-term than NEO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NEO’s TA Score shows that 3 TA indicator(s) are bullish while TMDX’s TA Score has 4 bullish TA indicator(s).

  • NEO’s TA Score: 3 bullish, 4 bearish.
  • TMDX’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, both NEO and TMDX are a bad buy in the short-term.

Price Growth

NEO (@Medical Specialties) experienced а +2.57% price change this week, while TMDX (@Medical Specialties) price change was +6.39% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +2.48%. For the same industry, the average monthly price growth was +2.32%, and the average quarterly price growth was +2.70%.

Reported Earning Dates

NEO is expected to report earnings on Jul 30, 2025.

TMDX is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Medical Specialties (+2.48% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
TMDX($2.4B) has a higher market cap than NEO($2.01B). TMDX YTD gains are higher at: 110.826 vs. NEO (-56.432). TMDX has higher annual earnings (EBITDA): -7.7M vs. NEO (-17.61M). NEO (415M) and TMDX (395M) have equal amount of cash in the bank . TMDX has less debt than NEO: TMDX (516M) vs NEO (612M). NEO has higher revenues than TMDX: NEO (592M) vs TMDX (242M).
NEOTMDXNEO / TMDX
Capitalization2.01B2.4B84%
EBITDA-17.61M-7.7M229%
Gain YTD-56.432110.826-51%
P/E Ratio49.50N/A-
Revenue592M242M245%
Total Cash415M395M105%
Total Debt612M516M119%
FUNDAMENTALS RATINGS
NEO vs TMDX: Fundamental Ratings
NEO
TMDX
OUTLOOK RATING
1..100
1850
VALUATION
overvalued / fair valued / undervalued
1..100
73
Overvalued
84
Overvalued
PROFIT vs RISK RATING
1..100
10041
SMR RATING
1..100
9341
PRICE GROWTH RATING
1..100
8936
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a75

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NEO's Valuation (73) in the Medical Or Nursing Services industry is in the same range as TMDX (84) in the Medical Specialties industry. This means that NEO’s stock grew similarly to TMDX’s over the last 12 months.

TMDX's Profit vs Risk Rating (41) in the Medical Specialties industry is somewhat better than the same rating for NEO (100) in the Medical Or Nursing Services industry. This means that TMDX’s stock grew somewhat faster than NEO’s over the last 12 months.

TMDX's SMR Rating (41) in the Medical Specialties industry is somewhat better than the same rating for NEO (93) in the Medical Or Nursing Services industry. This means that TMDX’s stock grew somewhat faster than NEO’s over the last 12 months.

TMDX's Price Growth Rating (36) in the Medical Specialties industry is somewhat better than the same rating for NEO (89) in the Medical Or Nursing Services industry. This means that TMDX’s stock grew somewhat faster than NEO’s over the last 12 months.

TMDX's P/E Growth Rating (100) in the Medical Specialties industry is in the same range as NEO (100) in the Medical Or Nursing Services industry. This means that TMDX’s stock grew similarly to NEO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NEOTMDX
RSI
ODDS (%)
N/A
Bearish Trend 4 days ago
70%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
80%
Bullish Trend 4 days ago
81%
Momentum
ODDS (%)
Bearish Trend 4 days ago
79%
Bearish Trend 4 days ago
74%
MACD
ODDS (%)
Bullish Trend 4 days ago
73%
Bearish Trend 4 days ago
78%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
76%
Bullish Trend 4 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
81%
Bullish Trend 4 days ago
89%
Advances
ODDS (%)
Bullish Trend 8 days ago
78%
Bullish Trend 4 days ago
86%
Declines
ODDS (%)
Bearish Trend 5 days ago
82%
Bearish Trend 11 days ago
81%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
84%
Bearish Trend 4 days ago
88%
Aroon
ODDS (%)
Bearish Trend 4 days ago
77%
Bullish Trend 4 days ago
89%
View a ticker or compare two or three
Interact to see
Advertisement
NEO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TMDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RAFBX35.970.25
+0.70%
American Funds AMCAP R2
SWLGX125.220.75
+0.60%
Schwab ® US Large-Cap Growth Idx
LYRIX28.740.09
+0.31%
Lyrical US Value Equity Institutional
JMNSX16.030.03
+0.19%
JPMorgan Research Market Neutral I
GGIJX13.23-0.01
-0.07%
Goldman Sachs Global Infras R6